AHG vs HCM vs ZLAB vs JFIN vs LEGN

For growth investors, Akso Health Group (AHG) is the stronger pick with 512.

1% revenue growth year-over-year, versus -24. 8% for HUTCHMED (China) Limited (HCM). Jiayin Group Inc. (JFIN) offers the better valuation at 1. 7x trailing P/E (0. 5x forward), making it the more compelling value choice. Analysts rate HUTCHMED (China) Limited (HCM) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Jiayin Group Inc.

(JFIN) is the cheapest at 1. 7x versus HUTCHMED (China) Limited at 59. 7x. On forward P/E, Jiayin Group Inc. is actually cheaper at 0. 5x.

Over the past 5 years, Akso Health Group (AHG) delivered a total return of +38.

5%, compared to -87. 6% for Zai Lab Limited (ZLAB). Over 10 years, the gap is even starker: HCM returned -0. 4% versus AHG's -97. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Akso Health Group (AHG) is the lower-risk stock at 0.

12β versus Jiayin Group Inc. 's 1. 21β — meaning JFIN is approximately 884% more volatile than AHG relative to the S&P 500. On balance sheet safety, Akso Health Group (AHG) carries a lower debt/equity ratio of 0% versus 41% for Legend Biotech Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Akso Health Group (AHG) is pulling ahead at 512.

1% versus -24. 8% for HUTCHMED (China) Limited (HCM). On earnings-per-share growth, the picture is similar: Zai Lab Limited grew EPS 38. 5% year-over-year, compared to -66. 0% for Legend Biotech Corporation. Over a 3-year CAGR, LEGN leads at 106. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Jiayin Group Inc.

(JFIN) is the more profitable company, earning 18. 2% net margin versus -913. 4% for Akso Health Group — meaning it keeps 18. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JFIN leads at 21. 5% versus -1125. 4% for AHG. At the gross margin level — before operating expenses — JFIN leads at 64. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Jiayin Group Inc.

(JFIN) trades at 0. 5x forward P/E versus 116. 2x for Legend Biotech Corporation — 115. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for LEGN: 105. 9% to $57. 89.

In this comparison, JFIN (16.

8% yield) pays a dividend. AHG, HCM, ZLAB, LEGN do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Akso Health Group (AHG) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

12)). Both have compounded well over 10 years (AHG: -97. 2%, ZLAB: -33. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (AHG (Financial Services) and HCM (Healthcare) and ZLAB (Healthcare) and JFIN (Communication Services) and LEGN (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: AHG is a small-cap high-growth stock; HCM is a small-cap quality compounder stock; ZLAB is a small-cap high-growth stock; JFIN is a small-cap deep-value stock; LEGN is a small-cap high-growth stock. JFIN pays a dividend while AHG, HCM, ZLAB, LEGN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.